ArticleDiabetes therapy : research, treatment and education of diabetes and related disorders2014
Insulin Degludec Aspart: The First Co-formulation of Insulin Analogues.
Article in Diabetes therapy : research, treatment and education of diabetes and related disorders, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 35 citations in OpenAlex.
- Insulin degludec/insulin aspart vs biphasic insulin aspart 30 twice daily in Japanese patients with type 2 diabetes: A randomized controlled trial.Journal of diabetes investigation · 2017Trial
- Safety and efficacy of insulin degludec/insulin aspart with bolus mealtime insulin aspart compared with standard basal-bolus treatment in people with Type 1 diabetes: 1-year results from a randomized clinical trial (BOOSTDiabetic medicine : a journal of the British Diabetic Association · 2017Trial
- An Overview of Currently Available Injectable Therapies in Diabetes: A Guide to Practitioners.Advances in therapy · 2025Review
- Stability Convergence in Antibody Coformulations.Molecular pharmaceutics · 2022Article
- Review
- Real-World Analysis of Rapid-Acting Insulin Analog Use and Its Blood Glucose Lowering Effect in Patients with Type 2 Diabetes Mellitus: Results from PASSION Disease Registry in Korea.Diabetes, metabolic syndrome and obesity : targets and therapy · 2022Article
- Practical guidance on the initiation, titration, and switching of basal insulins: a narrative review for primary care.Annals of medicine · 2021Review
- Outcomes of transition from premixed and intensive insulin therapies to insulin aspart/degludec co-formulation in type 2 diabetes mellitus: a real-world experience.Archives of medical science : AMS · 2021Article
- Use of Insulin Degludec/Insulin Aspart in the Management of Diabetes Mellitus: Expert Panel Recommendations on Appropriate Practice Patterns.Frontiers in endocrinology · 2021Review
- Stability enhancement in a mAb and Fab coformulation.Scientific reports · 2020Article
- Practical use of insulin degludec/insulin aspart in a multinational setting: beyond the guidelines.Diabetes, obesity & metabolism · 2020Review
- United States experience of insulin degludec alone or in combination for type 1 and type 2 diabetes.Drug design, development and therapy · 2017Review
- Article
- Injectable Coformulations in Diabetology.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2015Article
- Pediatric diabetes: Potential for insulin degludec.Indian journal of endocrinology and metabolism · 2014Article
- Insulin degludec and insulin degludec/insulin aspart in Ramadan: A single center experience.Indian journal of endocrinology and metabolismArticle
- Choice of Insulin in Type 2 Diabetes: A Southeast Asian Perspective.Indian journal of endocrinology and metabolismArticle
- Flexibility in insulin prescription.Indian journal of endocrinology and metabolismArticle
- Insulin degludec aspart: One-year real world experience.Indian journal of endocrinology and metabolismArticle
- Pragmatic use of insulin degludec/insulin aspart co-formulation: A multinational consensus statement.Indian journal of endocrinology and metabolismReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Insulin degludec/insulin aspart (IDegAsp) is the first soluble co-formulation which combines two insulin analogues, and provides effective basal and prandial glycemic coverage. It has been assessed as basal insulin in type 2 diabetes mellitus (T2DM), and as part of basal-bolus regime in both type 1 diabetes mellitus and T2DM. Insulin degludec has also been assessed as flexibly administered basal insulin in terms of time of administration. This review discusses data pertaining to the efficacy, safety, tolerability, and clinical potential of IDegAsp. The discussion includes comparisons of IDegAsp with basal as well as premixed insulin.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.